开放期刊系统

靶向表皮生长因子受体药物治疗肝癌的研究进展

李 源涵, 权 修权

摘要

在全球范畴内肝癌作为常见的恶性肿瘤之一,大部分患者确诊时便处于晚期阶段,其治疗及预后不佳。表皮生长因子受体(EGFR)在肝癌细胞呈现出高表达趋势,且与肝癌的发生、发展以及预后紧密关联。本文针对以EGFR为靶点的靶向药物应用于肝癌治疗的研究进展进行综述,包括作用于受体胞内区域的小分子酪氨酸激酶抑制剂,以及作用于受体胞外区域的单克隆抗体等药物的作用原理、临床治疗效果以及研究展望等方面。

关键词

肝癌;靶向表皮生长因子受体;临床研究

全文:

PDF

参考

[1]Li Y,Liu P,Liu S,et al.Halofuginone targets Serine/Glycine synthesis to reverse epidermal growth factor receptor Tyrosine Kinase

inhibitor resistance in lung adenocarcinoma[J].Phytomedicine,2025,143156788-156788.

[2]Shah H F,Nam S Y,Bang Y J,et al.Targeting vascular endothelial growth receptor-2(VEGFR-2):structural biology,functional

insights,and therapeutic resistance.[J].Archives of pharmacal research,2025,(prepublish):1-22.

[3]Xu Q,Chen X,Sun S,et al.Vascular Endothelial Growth Factor-Mimetic Peptide and Mitochondria-Targeted Antioxidant-Loaded

Hydrogel System Improves Repair of Myocardial Infarction in Mice.[J].Journal of biomedical materials research.Part A,2025,113(5):

e37924.

[4]Shah J N,Sura S,Shinde R,et al.Real-World Treatment Patterns and Clinical Outcomes Among Patients with Metastatic Renal Cell

Carcinoma Post-Immune-Oncology and Vascular Endothelial Growth Factor Receptor Targeted Therapies †[J].Cancers,2025,17(9):

1434-1434.

[5]Zhu F,Qiu J,Ye H,et al.The Prognostic Significance of Epidermal Growth Factor Receptor Amplification and Epidermal Growth

Factor Receptor Variant III Mutation in Glioblastoma:A Systematic Review and Meta-Analysis with Implications for Targeted

Therapy.[J].International journal of molecular sciences,2025,26(8):3539-3539.

[6]刘纪明.中晚期肝癌肝动脉灌注化疗的研究进展[J].中国卫生标准管理,2024,15(14):195-198.

[7]邓燕,段勇.原发性肝癌发病机制和药物治疗的研究进展[J].河北医学,2024,30(2):345-348.

作者简介:李源涵(1998-),男,在读医学硕士,研究方向:急危重症疾病研究;

通讯作者*

:权修权(1978-),男,中共党员,博士,主任医师,硕士研究生导师,研究方向:急危重症疾病研究。


(4 摘要 Views, 18 PDF Downloads)

Refbacks

  • 当前没有refback。